RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

Depression associated with molecular-level disturbance in body's 24-hour clock

Depression appears to be associated with a molecular-level disturbance in the body's 24-hour clock, new research suggests.

11 Nov 2010

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

10 Nov 2010

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

StemCellRegenMed, Inc. announces that a new stem cell gene and enzyme replacement treatment has been performed on a fourteen month old child with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a devastating disease that afflicts children primarily of parents of Jewish heritage and in very rare cases families of Eastern European background and the Cajun region in the U.S.A.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

Walter and Eliza Hall Institute researcher Dr Ross Dickins has been awarded a Sylvia and Charles Viertel Charitable Foundation Fellowship worth $AUD975,000 over five years.

10 Nov 2010

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

UC Davis researchers have found a new pathway for repairing DNA damaged by oxygen radicals. The results are published this week in the journal Proceedings of the National Academy of Sciences.

10 Nov 2010

MicroRNAs linked to failure of duct development in mammary glands

Max Planck researchers discover novel mechanism for vertebrate organ development. Hormones, growth factors and several proteins ensure that development occurs in the right way, at the right time. The components that cause breast development in mammals, for example, were thought to be largely known. However, as a team of scientists from Göttingen, Frankfurt and Hanover have now discovered, in the case of breast development, hormones and proteins do not account for the full story.

10 Nov 2010

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

A vaginal gel that affords both contraception and HIV protection using nanoparticles that carry bee venom is one of the bold, unconventional ideas that won a 2010 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation.

10 Nov 2010

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics plc announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.

10 Nov 2010

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

New research from Georgetown University Medical Center (GUMC) suggests that up to 40 percent of scleroderma patients will not be correctly diagnosed with the disorder using a new automated commercial screening test. The findings of the study will be presented Wednesday, November 10th at the Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia.

9 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Abbott, CHAI enter agreement to provide HIV testing to infants

Abbott and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children.

9 Nov 2010

Research reveals EBV virus infected cell manipulates cancer-producing cells

A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.

9 Nov 2010

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

NCRI launches first virtual biobank for prostate cancer research

The first virtual biobank dedicated to prostate cancer research has been launched today by the National Cancer Research Institute (NCRI). The UK Prostate Cancer Sample Collection Database will house details of around 10,000 biological samples taken from men in the UK with and without prostate cancer.

8 Nov 2010

New benchtop robotic workstation simplifies next-generation sequencing workflows

IntegenX, Inc. today at the 60th Annual American Society of Human Genetics Meeting announced the launch of their Apollo 324 System, a benchtop robotic workstation that automates the construction of DNA fragment libraries for next-generation sequencing.

8 Nov 2010

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.

4 Nov 2010

RNA News and Research

Further Reading

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Depression associated with molecular-level disturbance in body's 24-hour clock

Vertex to enroll additional treatment arm in telaprevir/VX-222 Phase 2 clinical trial for HCV

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

UC Davis researchers identify new pathway to repair oxidative-damaged DNA

MicroRNAs linked to failure of duct development in mammary glands

Contraceptive, antiviral gel using bee venom wins 2010 Gates Foundation grant

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

NEW ANA testing does not diagnose disorder in 40% of scleroderma patients

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Abbott, CHAI enter agreement to provide HIV testing to infants

Research reveals EBV virus infected cell manipulates cancer-producing cells

New COLD-PCR technology to detect EGFR gene mutation

New findings could help scientists devise optimal therapies for Friedreich's ataxia

NCRI launches first virtual biobank for prostate cancer research

New benchtop robotic workstation simplifies next-generation sequencing workflows

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo